Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 15/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729722 | 1.00 | KAT2B (0.47) | KAT2BLIPGALDH1A1MEN1CYP1A2 | |
| SCHEMBL22729667 | 1.00 | KAT2B (0.47) | KAT2BLIPGALDH1A1MEN1CYP1A2 | |
| SCHEMBL22729793 | 0.84 | ALDH1A1 (0.55) | KAT2BALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL22729682 | 0.82 | LIPG (0.53) | LIPGALDH1A1L3MBTL1 | |
| SCHEMBL22729729 | 0.77 | CNR2 (0.41) | KAT2BALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL22729726 | 0.77 | CNR2 (0.41) | KAT2BALDH1A1MEN1CYP1A2CYP3A4 | |
| SCHEMBL22729680 | 0.74 | LIPG (0.43) | LIPGALDH1A1KMT2ACNR1CNR2 | |
| Hydrochloric Acid SCHEMBL22729563 | 0.71 | KDM4E (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL22729690 | 0.71 | LIPG (0.45) | LIPGALDH1A1RIPK1CNR1CNR2 | |
| SCHEMBL22729628 | 0.69 | BRD4 (0.38) | ALDH1A1CYP1A2CYP2C9KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | KAT2B 592/4885LIPG 147/4885ALDH1A1 2626/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | KAT2B 591/4885LIPG 148/4885ALDH1A1 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.